Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review

Lee Nguyen, Lisa Raia, Bénédicte Lebrun-Vignes, Joe-Elie Salem

To cite this version:

Lee Nguyen, Lisa Raia, Bénédicte Lebrun-Vignes, Joe-Elie Salem. Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review. Frontiers in Pharmacology, Frontiers, 2021, 11, pp.619649. 10.3389/fphar.2020.619649. hal-03150327

HAL Id: hal-03150327
https://hal.sorbonne-universite.fr/hal-03150327
Submitted on 23 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review

Lee S. Nguyen1,2*, Lisa Raia3†, Bénédicte Lebrun-Vignes2,4 and Joe-Elie Salem2,5

1CMC Ambroise Paré, Research and Innovation—RICAP, Neuilly-sur-Seine, France, 2Sorbonne Université, Clinical Investigations Center Paris-Est, AP.HP.6 Pitié-Salpetriere University Hospital, INSERM, Paris, France, 3Intensive Care Medicine Department, AP.HP.Centre Cochin University Hospital, Paris, France, 4Creteil Paris-Est University, EpiderMe, Creteil, France, 5Department of Medicine, Cardio-Oncology Program, Vanderbilt University Medical Center, Nashville, TN, United States

Background: In patients with allogenic hematopoietic stem cell transplantation (allo-HSCT), immune-checkpoint inhibitors (ICI) are used to treat malignancy recurrence. However, ICI are also associated with graft vs. host disease (GVHD). In this pharmacovigilance analysis, we aimed to characterize cases of GVHD associated with ICI, drawn from the World Health Organization pharmacovigilance database, VigiBase®, and from literature.

Methods: We performed VigiBase® query of cases of GVHD associated with ICI. These cases were combined with those of literature, not reported in VigiBase®. The Bayesian estimate of disproportionality analysis, the information component, was considered significant if its 95% credibility interval lower bound was positive; denoting a significant association between GVHD and the suspected ICI. Time to onset between ICI and GVHD onset and subsequent mortality were assessed.

Results: Disproportionality analysis yielded 93 cases of GVHD associated with ICI (61.8% men, median age 38 [interquartile range = 27; 50] years). Cases were mostly associated with nivolumab (53/93, 57.0%), pembrolizumab (23/93, 24.7%) and ipilimumab (12/93, 12.9%) monotherapies. GVHD events occurred after 1 [1; 5.5] injection of ICI, with a time to onset of 35 [IQR = 14; 176] days. Immediate subsequent mortality after GVHD was 24/93, 25.8%. There was no significant difference in mortality depending on the molecule (p = 0.41) or the combination regimen (combined vs. monotherapy, p = 0.60). Previous history of GVHD was present in 11/18, 61.1% in cases reported in literature.

Conclusion: In this worldwide pharmacovigilance study, disproportionality yielded significant association between GVHD and ICI, with subsequent mortality of 25.8%. Previous history of GVHD was reported in more than half of cases.

Clinicaltrials.gov identifier: NCT03492242

Keywords: immunotherapy, pharmacovigilance, vigibase®, graft-versus-host disease, adverse (side) effects
BACKGROUND

Immune checkpoint inhibitors (ICI) may be used to treat aggressive hematologic malignancies, either in refractory or relapsed lymphoma frequently before being treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT) or in relapse after allo-HSCT. Indeed, in both situations, relapse mechanisms include immune escape by the tumor, T-cell anergy, down-regulation of regulatory T cells and activation of immune checkpoints (Barrett and Battiwalla, 2010). They include drugs targeting programmed death-1 receptor (anti-PD-1), its ligand (anti-PD-L1) and cytotoxic T lymphocyte antigen-4 (anti-CTLA-4).

Like other therapies used in these indications (i.e., donor lymphocytes infusion, chemotherapy, immunotherapy, CAR T cell therapy), the aim of ICI is to enhance the immune system so that it may be effective against malignancy, by restoring T-cell function, activating lymphocytes and inducing a sustainable graft-versus-tumor (GVT) effect.

However, ICI are associated with immune-related adverse events, secondary to the over-activation of the immune system, which may, in turn, cause auto-immune-like complications, including graft-versus-host disease (GVHD). GVHD is serious adverse event in patients with allo-HSCT, initially described as an aggravated manifestation of regular inflammation, in which, donor lymphocytes interact with recipient antigens which may cause multi-organ dysfunction (Ramachandran et al., 2019).

Previously, cohort studies showed that ICI used before allo-HSCT were associated with an incidence of GVHD varying from 41 to 56% (Merryman et al., 2017; Ijaz et al., 2019). When used after allo-HSCT, the incidence depended whether there was a history of previous GVHD (55%) or if it was the first episode (30%) (Haverkos et al., 2017; Herbaux et al., 2018).

To comfort these results yielded from cohort studies; in the present work, we used disproportionality methodology to present characteristics of GVHD following ICI administration. This method is based on a large pharmacovigilance database, VigiBase®, which collects worldwide reports of drug-related adverse events in the World Health Organization network (Lindquist 2008). In addition, whenever possible, we combined the individual reports yielded from VigiBase® to de-duplicated cases reported in the literature to expand the cohort.

METHODS

Study Design

This work combines a worldwide pharmacovigilance observational case-control cross-sectional study focusing on GVHD related to the usage of ICI, and a systematic literature case report analysis. The pharmacovigilance part relies on VigiBase®, a database encompassing 22 million individual case safety reports (ICSR) received worldwide (Lindquist 2008). It is freely accessible upon request, increasing possibilities for external validation (“VigiAccess.” from http://www.vigiaccess.org/).

ICSRs include administrative information (country, type of report, qualification of reporter), patient data (age, sex), date of onset of reaction(s) and nature of the outcome using the latest version of MedDRA (Medical Dictionary for Regulatory Activities) terms (currently v22.1). Drug(s) involved (name, drug start and stop dates, indication, dose) are also indicated.

We searched for cases flagged with MedDRA preferred terms (PT) reflecting GVHD (see below), and associated with ICI molecules (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab, tremelimumab and cemiplimab) from VigiBase® creation through January 05, 2020.

This work is ancillary to the Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction (CHImERA) registry (clinicaltrials.gov registry number NCT03492242).

Disproportionality Analyses

To assess whether a GVHD adverse event was associated with an ICI molecule in VigiBase®, we used disproportionality analysis (also known as case–non-case analysis) methodology. Briefly, the estimate of disproportionality analysis can be calculated by the information component (IC) for which IC025 is the lower end of its 95% credibility interval. A positive IC025 is statistically significant (Bate et al., 1998; Norén et al., 2013). The IC calculation was based on the number of GVHD reported with each ICI molecule, vs. all ADR with all medicines reported in VigiBase®. Like others, our research group previously used this method and database to describe the spectrum of cardiovascular diseases and other immune-related adverse events associated with ICI (Salem et al., 2018; Nguyen et al., 2020).

Calculation of the IC using a Bayesian confidence propagation neural network was developed and validated by the Uppsala Monitoring Center as a flexible, automated indicator value for disproportionate reporting that compares observed and expected drug–ADR associations to find new drug–ADR signals with identification of probability difference from the background data (full database) (Bate et al., 1998). Probabilistic reasoning in intelligent systems (information theory) has proved to be effective for the management of large datasets, is robust in handling incomplete data, and can be used with complex variables. The information theory tool is ideal for finding drug–ADR combinations with other variables that are highly associated compared with the generality of the stored data (Bate, Lindquist et al., 1998). Several examples of validation with the IC exist, showing the power of the technique to find signals sooner after drug approval than by a regulatory agency (e.g., an association between captopril and coughing), and to avoid false positives, whereby an association between a common drug and a common ADR occurs in the database only because the drug is widely used and the ADR is frequently reported (Bate, Lindquist et al., 1998; Norén, Hopstadius et al., 2013). Furthermore, our group recently published several studies using VigiBase® and disproportional reporting calculation to characterize and identify new drug–ADR associated signals, which were subsequently corroborated by preclinical mechanistic studies or prospective cohorts (Salem et al., 2018; Salem et al., 2019a; Salem et al., 2019b; Salem et al., 2019c).
The statistical formula is as follows:

\[
\text{IC} = \log_2 \left( \frac{(N_{\text{observed}} + 0.5)}{(N_{\text{expected}} + 0.5)} \right)
\]

where

\[
N_{\text{expected}} = \left( \frac{N_{\text{drug}} \times N_{\text{effect}}}{N_{\text{total}}} \right)
\]

\(N_{\text{expected}}\) is the number of case reports expected for the drug–ADR combination.

\(N_{\text{observed}}\) is the actual number of case reports for the drug–ADR combination.

\(N_{\text{drug}}\) is the number of case reports for the drug, regardless of ADR.

\(N_{\text{effect}}\) is the number of case reports for the ADR, regardless of the drug.

\(N_{\text{total}}\) is the total number of case reports in the database.

\(\text{IC}_{0.25}\) is the lower end of a 95% credibility interval for the IC. A positive \(\text{IC}_{0.25}\) value (\(>0\)) is the traditional threshold deemed statistically significant. \(\text{IC}_{0.25}\) values have only been validated for comparison of drug-specific ADR vs. the full database and cannot be used to compare disproportionate reporting among different ICI regimens. All patients were included in these analyses.

List of all MedDRA preferred terms (PT) related to GVHD, used in VigiBase® query.

- Acute graft vs. host disease (PT)
- Acute graft vs. host disease in intestine (PT)
- Acute graft vs. host disease in liver (PT)
- Acute graft vs. host disease in skin (PT)
- Chronic graft vs. host disease (PT)
- Chronic graft vs. host disease in intestine (PT)
- Chronic graft vs. host disease in liver (PT)
- Chronic graft vs. host disease in skin (PT)
- Graft vs. host disease (PT)
- Graft vs. host disease in eye (PT)
- Graft vs. host disease in gastrointestinal tract (PT)
- Graft vs. host disease in liver (PT)
- Graft vs. host disease in lung (PT)
- Graft vs. host disease in skin (PT)

**Literature Review**

A systematic literature review of all published cases of GVHD associated with ICI was performed, spanning from January 1st, 2010 to February 1st, 2020, on MEDLINE using PubMed® search engine. The methodological search strategy included keywords associated with Medical Subject Headings (MeSH) terms related to ICI and GVHD: “immune checkpoints inhibitors” OR (“immune” AND “checkpoints”) OR (“checkpoint” AND “inhibitor”) OR “nivolumab” OR “pembrolizumab” OR “ipilimumab” OR “cemiplimab” OR “avelumab” OR “durvalumab” OR “atezolizumab” OR “PD-1 blockade”) AND (“graft vs. host disease” OR (“graft vs. host” AND “disease”) AND (“Allogeneic stem cell transplantation” OR (“allogeneic” AND “stem cell transplant”). From this search, 715 articles were found which contained any of these terms, but the combination of these terms in the format of case reports or case series after adequate filtering yielded 22 cases.

**Statistics**

Continuous variables are presented as median [interquartile-range] and categorical variables as number (percentage), with relevant comparison tests, accounting for data distribution. GraphPad Prism v6.0 (GraphPad Software, California, United States) was used for statistics and figures, except Figure 2 drawn using R software (R project, worldwide community project).

**RESULTS**

Overall, we included 93 deduplicated cases (91 reported in VigiBase® and 22 in literature, among which 20 were reported host disease in liver (PT), Graft vs. host disease in lung (PT), Graft vs. host disease in skin (PT).
in VigiBase® that we accounted for). In VigiBase®, disproportionality analysis yielded significant association between GVHD events and ICI molecules, with an IC = 2.0 and IC025 = 1.7 (see Figure 1). The first reported case was with ipilimumab in 2014. The most represented drug-ADR association was nivolumab with GVHD (n = 33, IC = 2.4, IC025 = 1.9). The most common ICI indications reported were Hodgkin disease in 47/81, 58.0% and non-Hodgkin lymphoma in 14/81, 17.3%. ICI were prescribed in monotherapy, in 88/93, 94.6% (as compared to combination therapy involving several ICI). There was no relevant information regarding GVHD grade in VigiBase®.

In the aggregated dataset of 93 cases, men represented 42/68, 61.8% of cases (Table 1). Median age was 38 [interquartile range (IQR) = 27; 50] years. Events occurred after a median of 1 [IQR = 1; 5.5] ICI injection. Median time to onset of GVHD after first ICI injection was 35 [IQR = 14; 176] days (data available in 19/93, 20.4%).

Overall mortality associated with ICI-associated GVHD was 24/93, 25.8%. This mortality was that reported in VigiBase® and implies a very short follow-up after the episode (less than a month). Therapy regimen (combination vs. monotherapy) did not affect subsequent mortality (respectively, 22/88, 25.0% vs. 2/5, 40.0%, p = 0.60). Mortality was not affected by the type of molecule (p = 0.41). Immune-related adverse events were co-reported in 23/93, 24.7%, mostly with hepatitis in 6/23, 26.1%.

In case reports extracted from literature (Singh et al., 2016; Boekstegers et al., 2017; Braun et al., 2017; Haverkos et al., 2017; Klobuch et al., 2017; Onizuka et al., 2017; Herbaux et al., 2018; Charles et al., 2019; Kim et al., 2019; Minson et al., 2019), when mentioned, ICI was indicated for disease relapse after allo-HSCT in 17/22, 77.3%. In one case of nivolumab-associated GVHD, biopsy showed PD-L1 expression in skin, liver and muscular tissues (those with active GVHD) (Charles et al., 2019).

Finally, we observed 11/18, 61.1% of patients had prior history of GVHD before ICI administration, although this information was lacking in 75/93, 80.6% of reports.

DISCUSSION

In this work, we analyzed GVHD related to ICI, by combining a systematic disproportionality analysis relying on the WHO pharmacovigilance database, VigiBase®; and case-reports drawn from literature, amounting a total of 93 cases to further describe risk factors of GVHD and prognosis.

In the cases we reviewed, ICI were mostly indicated for disease relapse after allo-HSCT, aiming at restauration of T-cell function and appropriate graft-versus-tumor effect (Godfrey et al., 2017). Whether previous GVHD is an additive or synergistic risk factor of GVHD remains to be explored, however better characterization of GVHD events may benefit from adding any prior history of GVHD, which remains the risk factor most associated with this event. Previous reports confirmed that history of GVHD was a risk factor, even for GVHD...
related to ICI after allo-HSCT (12/17, 70.6% vs. 5/17, 29.4%) (Haverkos et al., 2017).

While VigiBase® cannot be used to compute true incidence of adverse serious events, in this worldwide pharmacovigilance database analysis, we confirmed a significant association between GVHD and ICI administration. Time to onset was 35 days after first treatment, however, residual effects of ICI, due to a long half-life and extended pharmacodynamic effects, even substantially beyond its administration prior to allo-HSCT (Geraud et al., 2021). Indeed, expression of PD-1 on T cells was found significantly decreased up to 6 months after allo-HSCT, despite a last dose of ICI more than a month prior (Merryman

### TABLE 1 | Reports of graft vs. host disease (GVHD) associated with immune checkpoint inhibitors (ICI) aggregated from VigiBase® (thru January 05, 2020) and systematic literature search (thru February 2020).

| n/N (%) | Data available, n (%) |
|---------|-----------------------|
| **Reporting region** | All |
| United States | 50/93 (53.8) |
| Europe | 23/93 (24.7) |
| Australia | 7/93 (7.5) |
| Asia | 13/93 (14.0) |
| **Reporting year** | All |
| 2019 | 32/93 (34.4) |
| 2018 | 19/93 (20.4) |
| 2017 | 29/93 (31.2) |
| 2016 | 9/93 (9.7) |
| 2015 | 9/93 (9.7) |
| 2014 | 1/93 (1.1) |
| **Reporters** | 89/93 (95.7) |
| Healthcare professional | 82/89 (92.1) |
| Non-healthcare professional | 7/89 (7.9) |
| **Reports in the course of clinical studies** | All |
| Sex | 68/93 (73.1) |
| Men | 42/68 (61.8) |
| Women | 26/68 (38.2) |
| Age at onset, mean ± SD, years | 39.03 ± 16.25, 61/93 (65.6) |
| (min-max) | (3–74) |
| **Death** | All |
| 24/93 (25.8%) |
| **Suspected drugs** | All |
| Only ICI | 69/93 (74.2) |
| ICI + 1 other drug | 11/93 (11.8) |
| ICI + ≥2 other drugs | 13/93 (14.0) |
| **Drugs** | All |
| Monotherapy with anti PD-1/PD-L1 | 53/93 (57.0) |
| Nivolumab | 23/93 (24.7) |
| Pembrolizumab | 12/93 (12.9) |
| Ipilimumab | 5/93 (5.4) |
| Combination therapy | 81/93 (87.1) |
| Nivolumab + Ipilimumab | 35 [14–176], 19/93 (20.4) |
| **Indications for ICI** | (min-max) |
| Hodgkin disease | 17/22 (77.3) |
| Non-hodgkin lymphoma | 47/81 (58.0%) |
| Other | 14/81 (17.3%) |
| **Timing of ICI administration** | 22/93 (23.7) |
| Before allo-HCST | 5/22 (22.7) |
| After allo-HCST | 17/22 (77.3) |
| **Type of graft** | 12/17 (70.6) |
| Matched related donor | 1/17 (5.9) |
| Matched unrelated donor | 4/17 (23.5) |
| Cord blood | 18/83 (19.4) |
| **Previous GVHD** | No |
| Yes | 11/18 (61.1) |
| No | 7/18 (39.9) |

**Note:** Data were taken from VigiBase® (thru January 05, 2020) and systematic literature search (thru February 2020).
In patients not treated by ICI, PD-1 expression after allo-HSCT was also associated with increased risk of mortality (Schade et al., 2016).

Literature search yielded in one case of nivolumab-associated GVHD, a PD-L1 expression in skin, liver and muscular tissues (those with active GVHD) (Charles et al., 2019). As of yet, PD-L1 expression has not been described in regular GVHD reports (Ramachandran et al., 2019). CROSSTALK between PD-1/PD-L1 and CTLA4 may play an important role in GVHD mechanisms. Indeed, while ICI may induce GVHD, reversion by abatacept was described (Nahas et al., 2018).

Interestingly, we found similar results as those found in the largest dataset to date, of GVHD due to ICI, aggregating 283 cases from several studies albeit with a reported overall mortality after GVHD of 11%, lower than that observed in our study. There were 107 cases occurring prior to allo-HSCT, and 176 after, akin to the results we observed in our dataset (Ijaz et al., 2019).

Our findings support the fact that ICI use in patients with allo-HSCT needs to be carefully monitored, as these patients are at high risk of developing GVHD. Regarding event prediction, risk factors of developing immune-related adverse events are currently under investigation (Shankar et al., 2020), and biomarkers involved in the mTOR pathway have been suggested (Esfahani et al., 2019).

We acknowledge several limitations to the present work. First, retrospective pharmacovigilance analyses present inherent intrinsic limitations; while disproportionality reporting used here (ICOb3) have been demonstrated to accurately to identify signals of cardiovascular adverse events associated with anticancer drugs in various settings (Salem et al., 2018; Salem et al., 2019b), risk of false signals remain possible. Reporting and publication bias need to be addressed: in most cases, details on patients such as previous history of GVHD were not mentioned in VigiBase® making it hard to assess its weight into the added risk of developing GVHD after ICI administration. Similarly, indications for ICI treatment or previous HSCT were not always clearly stated, making it hard to categorize these events. Cotreatments used to treat lymphoma relapse were not always stated, which makes the assertion of cumulative risk of GVHD difficult, as previous other treatments used in these indications may also be associated with GVHD, such as donor lymphocytes infusions. Finally, these analyses do not allow the computation of true incidence, as by essence, disproportionality analyses report relative incidences. True incidence would require a denominator which would include all worldwide prescriptions of ICI in the study period. Yet, our observations confirm several cohort studies and we hope these findings may help oncologists, hematologists and pharmacovigilance specialists to better interact in order to improve reporting and management of GVHD related to ICI intake.

**CONCLUSION**

This worldwide pharmacovigilance database analysis confirmed a significant association between GVHD and ICI.

**DATA AVAILABILITY STATEMENT**

Publicly available datasets were analyzed in this study. This data can be found here: http://www.vigiaccess.org.

**AUTHOR CONTRIBUTIONS**

LN and LR equally contributed to the manuscript. They wrote the draft, performed analyses, reviewed literature. BL-V provided VigiBase data and provided critical review to the manuscript. J-ES supervised the project, performed analyses and provided critical review to the manuscript.

**REFERENCES**

Barrett, A. J., and Battiwalla, M. (2010). Relapse after allogeneic stem cell transplantation. *Expert. Rev. Hematol.* 3 (4), 429–441. doi:10.1586/ehr.10.32

Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., et al. (1998). A Bayesian neural network method for adverse drug reaction signal generation. *Eur. J. Clin. Pharmacol.* 54 (4), 315–321. doi:10.2165/00001088-199854040-00005

Boelsteegers, A. M., Blaaschke, F., Schmidt, I., Wiebhöing, V., Immler, S., Hoffmann, F., et al. (2017). MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD. *Bone Marrow Transplant.* 52 (8), 1221–1224. doi:10.1038/bmt.2017.107

Braun, M., Dunavin, N., Pike, M., Dias, A. L., Lin, T. L., Shune, L., et al. (2017). Successful management of treatment-emergent chronic graft-versus-host disease of the liver following nivolumab for relapsed hodgkin’s lymphoma after allogeneic stem cell transplant. *Blood* 130 (Suppl. 1), 5492

Charles, J., Giovannini, D., Terzi, N., Schwabe, C., Sturm, N., Masson, D., et al. (2019). Multi-organ failure induced by Nivolumab in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. *Blood* 132 (1), 94–99. doi:10.1182/blood-2018-02-811174

Esfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., et al. (2019). Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. *Nat. Commun.* 10 (1), 4712. doi:10.1038/s41467-019-12628-1

Geraud, A., Gougis, P., Vozy, A., Anquetil, C., Allenbach, Y., Romano, E., et al. (2019). Clinical Pharmacology and interplay of immune checkpoint Agents: a yin-yang balance. *Ann. Rev. Pharmacol. Toxicol.* 61, 85. doi:10.1146/annurev- pharmacox-022820-093805

Goodyear, J., Bishop, M. R., Syed, S., Hyjek, E., and Kline, J. (2017). PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. *J. Immunother. Cancer* 5 (1), 11. doi:10.1186/s40425-017-0211-z

Haverkos, B. M., Abbott, D., Hamadani, M., Armand, P., Flowers, M. E., Merryman, R., et al. (2017). PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. *Blood* 130 (2), 221–228. doi:10.1182/blood-2017-01-761346

Herbaux, C., Merryman, R., Devine, S., Armand, P., Houot, R., Morschhauser, F., et al. (2018). Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. *Blood* 132 (1), 9–16. doi:10.1182/blood-2018-02-811174

Ijaz, A., Khan, A. Y., Malik, S. U., Faridi, W., Fraz, M. A., Usman, M., et al. (2019). Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. *Biol. Blood Marrow Transplant.* 25 (1), 94–99. doi:10.1016/j.bbmt.2018.08.028
